Funder: The Honorable Tina Brozman Foundation (Tina's Wish)
Due Dates (Anticipated): January 2027 (Full proposal) | September 2027 (Letter of intent)
Funding Amounts: A2C: up to $1,000,000 over two years; Rising Star: $200,000 over two years; Team Science: $500,000 over two years
Summary: Tina’s Wish supports innovative ovarian cancer early detection and prevention research, including clinically ready biomarker projects through its Acceleration to Clinic Grant.
Key Information: A2C requires validated human-sample assays beyond biomarker discovery; full applications are by invitation only.
Description
Tina’s Wish funds research to develop effective early detection screens and prevention strategies for ovarian cancer. Its Rising Star Grant supports promising early-career researchers taking risks on innovative projects, while its Team Science Grant encourages collaborative research. The Acceleration to Clinic (A2C) Grant adds funding and expert advisory resources for investigator teams whose ovarian cancer biomarkers have reached defined clinical readiness under the National Cancer Institute’s Early Detection Research Network (EDRN) framework.
A2C supports rigorous, milestone-driven validation and preparation for investigator-initiated clinical trials. Its scope includes early detection and screening tests, ovarian cancer interception strategies, and multi-analyte or composite biomarker signatures. The program aims to position projects for clinical translation within one year after funding ends and for subsequent external funding.
